Bevacizumab in cervical cancer: a step forward for survival
Mené sur 452 patientes atteintes d'un cancer du col de l'utérus de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du bévacizumab à une chimiothérapie
Cervical cancer is the fourth most common cancer affecting women, with more than 500 000 new cases and more than 260 000 deaths worldwide in 2012.1 This statistic is disturbing given the fact that with the introduction of screening and HPV vaccination programmes, cervical cancer is now a preventable and curable disease. Once the disease is not salvageable, any treatment offered to patients is palliative. By contrast with most other solid cancers, the highest incidence of cervical cancer is in young women, with more than half of diagnoses occurring in women aged younger than 45 years.
The Lancet , commentaire, 2016